BLOGIR-3 pills for dissolving 5mg, 10pcs

Composition

One tablet for resorption contains: Active ingredient:  desloratadine 5 mg; excipients: mannitol – 133,5 mg, microcrystalline cellulose – 15,0 mg, croscarmellose sodium 6.0 mg of potassium polacrilin – 5.0 mg, aspartame – 3.0 mg, magnesium stearate – 1.7 mg, flavor, tutti-Frutti (flavouring substances, maltodextrin, propylene glycol E 1520, modified starch E 1450) – 0.75 mg, dye iron oxide red – 0.7 mg, citric acid monohydrate – q. s.

Pharmacological action

Pharmacodynamically an antihistamine for long periods. It is the primary active metabolite of loratadine. Selectively blocks the activity of peripheral H histamine receptors. Inhibits the release of histamine from mast cells. It inhibits a cascade of allergic inflammatory reactions, including the release of anti-inflammatory cytokines, including interleukins IL-4, IL-6, IL-8, IL-13, and the release of adhesion molecules such as P-selectin. Thus, it prevents the development and facilitates the course of allergic reactions, has an antipruritic and antiexudative effect, reduces capillary permeability, prevents the development of tissue edema, smooth muscle spasm. The drug does not affect the central nervous system, has almost no sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions. It does not cause prolongation of the QT interval on the ECG. Pharmacokineticsabsorption After oral use, desloratadine is well absorbed in the gastrointestinal tract, and is detected in blood plasma 30 minutes after oral use. The maximum concentration of Cmax is reached after approximately 3 hours. Distribution The binding of desloratadine to plasma proteins is 83-87%. When used in adults and adolescents for 14 days at a dose of 5 mg to 20 mg once a day, there were no signs of clinically significant accumulation of desloratadine. Simultaneous intake of food or grapefruit juice does not affect the distribution of desloratadine (when taken at a dose of 7.5 mg once a day). It does not cross the blood-brain barrier. Metabolism It undergoes intensive metabolism in the liver by hydroxylation to form 3-OH-desloratadine, combined with glucuronide. It is not an inhibitor of the CYP3A4 and CYP2D6 isoenzymes and is not a substrate or inhibitor of P-glycoprotein. Deduction Desloratadine is eliminated from the body as a glucuronide compound and in small amounts (less than 2%) by the kidneys and through the intestines (less than 7%) in unchanged form. The elimination half-life is 27 hours on average.

Indications

• Allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus discharge, itchy nose, itchy palate, itchy and red eyes, watery eyes);
• urticaria (reduction or elimination of skin itching, rash).

Contraindications

Hypersensitivity to the components of the drug; pregnancy and lactation; age up to 12 years; phenylketonuria. Caution In the presence of severe renal insufficiency, the drug should be taken with caution.

Adverse effects

the adverse reactions are classified according to the recommendations of the world health organization: very often – at least 10%; often – not less than 1% but < 10%; infrequently – no more than 0.1% but < 1%; rarely – not less than 0.01%, but less than 0.1%; very rarely – less than 0.01%, including individual messages. Most common undesirable effects (>1/100 to >Very rare (: From the central nervous system: hallucinations, dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions. From the cardiovascular system: tachycardia, palpitations. From the digestive system: abdominal pain, nausea, vomiting, dyspepsia, diarrhea. Liver and biliary tract disorders:  increased activity of hepatic transaminases, increased bilirubin concentration, hepatitis. Musculoskeletal system disorders: myalgia. From the immune system: anaphylaxis, angioedema, shortness of breath, pruritus, rash, including urticaria, photosensitization. If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Interactions with multiple co-use of desloratadine with ketoconazole, erythromycin, azithromycin, fluoxetine and cimetidine clinically significant changes in the concentration of desloratadine in plasma were not detected. BLOGIR-3® does not enhance the effects of alcohol on the central nervous system. Food intake does not affect the effectiveness of the drug.

How to take, course of use and dosage

Inside, regardless of food intake. Carefully open the blister and remove the tablet without breaking it. The resorption tablet is placed on the tongue, where it dissolves, after which it is swallowed with saliva, without washing down with water or other liquid. The tablet should be taken immediately after opening the blister. Adults and teenagers over 12 years old:  take 1 tablet for resorption (5 mg) once a day to reduce the symptoms of allergic rhinitis (including seasonal and year-round allergic rhinitis) and urticaria. For seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days a week or less than 4 weeks a year), it is necessary to assess the course of the disease. If symptoms disappear, the drug should be discontinued, and if symptoms reappear, the drug should be resumed. In case of year-round (persistent) allergic rhinitis (if there are symptoms lasting more than 4 days a week or more than 4 weeks a year), the drug should be taken during the entire period of exposure to the allergen.

Overdose

In clinical trials, no clinically significant adverse effects were observed when desloratadine was administered at a dose of up to 45 mg (9 times the therapeutic dose). Treatment: In case of overdose, standard measures are taken to remove the Active ingredient from the gastrointestinal tract. Symptomatic and supportive care is recommended. Desloratadine is not eliminated by hemodialysis, and the effectiveness of peritoneal dialysis has not been established.

Special instructions

Influence on the ability to drive vehicles and mechanisms

At the recommended dose, the drug does not affect the ability to drive vehicles or mechanisms.

However, in very rare cases, some patients may experience drowsiness while taking desloratadine, which may affect their ability to drive vehicles or operate machinery.

Storage conditions

At a temperature not exceeding 25 °C. Keep out of reach of children!

Shelf

life is 3 years.

Active ingredient

Desloratadine

Dosage form

solution for oral use

Description

For adults, Children over 12 years of age

Indications

Dermatitis, Allergy, Runny Nose, Conjunctivitis, Pollinosis, Urticaria